Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMpac Group Plc Regulatory News (MPAC)

Share Price Information for Mpac Group Plc (MPAC)

Share Price is delayed by 15 minutes
Get Live Data
210.00    0.00 (0.00%)
Bid:
205.00
Ask:
215.00
Spread: 10.00 (4.878%)
Market Cap: £63.15m
MPAC Live PriceLast checked at - London Stock Exchange

Intraday Mpac Group Plc Share Chart

Schedule 1 - Molins Plc

20 May 2014 11:32

RNS Number : 5805H
AIM
20 May 2014
Β 

ο»Ώ

Β 

Β 

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Molins PLC

Β 

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

Rockingham Drive

Linford Wood East

Milton Keynes

MK14 6LY

Β 

COUNTRY OF INCORPORATION:

England and Wales

Β 

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.molins.com

Β 

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

The principal activities of Molins PLC (the "Company or the "Group") are the design, manufacture and servicing of processing and quality control instrumentation and machinery and the provision of analytical laboratory services for the fast-moving consumer goods, healthcare and pharmaceutical sectors. The Group is organised into three divisions - Scientific Services, Packaging Machinery and Tobacco Machinery.

Β 

The Group's main country of operation is the UK with its registered office and head office based in Milton Keynes. The Group's overseas locations include facilities and offices in the USA, Canada, Russia, the Netherlands, the Czech Republic, Singapore and Brazil.

Β 

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

20,171,540 ordinary shares of 25 pence each.

Β 

No shares are held in treasury.

Β 

The shares are freely transferable and have no restrictions placed on them.

Β 

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Capital to be raised on admission: n/a

Β 

Anticipated market capitalisation on admission: Β£35 million

Β 

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

30.3%

Β 

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED:

None

Β 

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Avril Palmer-Baunack (Chairman)

Richard (Dick) Clive Hunter (Chief Executive)

David John Cowen (Group Finance Director)

John Lewis Davies (Non-Executive Director)

Philip James Moorhouse (Non-Executive Director)

Β 

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Shareholders as at before and after admission:

Β 

Schroder Investment Management Limited

26.08%

Barclays Wealth

6.06%

River & Mercantile Asset Management LLP

5.78%

Charles Stanley

5.06%

Hargreaves Lansdowne Asset Management

4.27%

TD Direct Investing

3.75%

EES Trustees International Limited

3.38%

Mr G V L Oury

3.07%

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

None

Β 

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

(i) 31 December

(ii) n/a

(iii) 30 September 2014 (interim results for the six month period to 30 June 2014)

30 June 2015 (annual results for the full year to 31 December 2014)

30 September 2015 (interim results for the six month period to 30 June 2015)

Β 

EXPECTED ADMISSION DATE:

19 June 2014

Β 

NAME AND ADDRESS OF NOMINATED ADVISER:

Panmure Gordon (UK) Limited

One New Change

London

EC4M 9AF

United Kingdom

Β 

NAME AND ADDRESS OF BROKER:

Panmure Gordon (UK) Limited

One New Change

London

EC4M 9AF

United Kingdom

Β 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

n/a

Β 

DATE OF NOTIFICATION:

20 May 2014

Β 

NEW/ UPDATE:

NEW

Β 

QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:

THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED:

Premium segment of the UKLA Official List / Main Market of the London Stock Exchange

Β 

THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED:

28 July 1976

Β 

CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORY REQUIREMENTS INVOLVED IN HAVING ITS SECURITIES TRADED UPON SUCH A MARKET OR DETAILS OF WHERE THERE HAS BEEN ANY BREACH:

The Company has adhered to the legal and regulatory requirements of the Official List / Main Market.

Β 

AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THE LAST TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE:

www.molins.com

Β 

DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING STRATEGY:

The Company's strategy to achieve its objective of growth across its three divisions can be summarised as follows:

Β 

-

Increasing the Group's exposure to attractive global industry sectors - nutrition, beverages, healthcare, pharmaceuticals and tobacco

-

Investment in the development of innovative new products and services, the Group's infrastructure and acquisitions in adjacent growth markets

-

Driving operational efficiency through supply chain and customer service excellence, capitalising on opportunities to realise synergies

Β 

A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURRED SINCE THE END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED:

There has been no significant change in the financial or trading position of Molins PLC since 31 December 2013, being the end of the last financial period for which audited financial statements have been published.

Β 

A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT THE WORKING CAPITAL AVAILABLE TO IT OR ITS GROUP WILL BE INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION:

The Directors of Molins PLC have no reason to believe that the working capital available to the Company or its Group will be insufficient for at least 12 months from the date of its admission.

Β 

DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES:

None

Β 

A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES:

Settlement will be through the CREST system for dealings in ordinary shares held in uncertificated form. Shares can also be dealt with in certificated form.

Β 

A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES:

www.molins.com

Β 

INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC:

See Appendix 1, available at www.molins.com

Β 

A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE A FINANCIAL YEAR END NOT MORE THEN NINE MONTHS PRIOR TO ADMISSION AND INTERIM RESULTS WHERE APPLICABLE. THE ACCOUNTS MUST BE PREPARED IN ACCORDANCE WITH ACCOUNTING STANDARDS PERMISSIBLE UNDER AIM RULE 19:

www.molins.com/investor-relations/financial-information

Β 

THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TREASURY:

None

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
PAABGGDUBXDBGSG
Date   Source Headline
9th Jun 202610:36 amRNSDirector Purchases of Ordinary Shares
8th Jun 20267:00 amRNSTrading Update and Sale of Lambert for up to £20m
15th May 20267:00 amRNSAvailability of 2025 Annual Report & Notice of AGM
24th Apr 20262:00 pmRNSAIM Rule 17 Disclosure
21st Apr 20267:01 amRNSChief Financial Officer Succession
21st Apr 20267:00 amRNSFull Year Results
24th Mar 20267:00 amRNSNotice of Results and Investor Presentation
18th Feb 20264:52 pmRNSChange of Registered Office
2nd Feb 20263:19 pmRNSDirector/PDMR Shareholding
15th Jan 20267:00 amRNSAppointment of Senior Independent Director
15th Jan 20267:00 amRNSFull Year trading update and notice of results
31st Oct 202511:54 amRNSHolding(s) in Company
24th Oct 202510:55 amRNSDirector/PDMR Shareholding
2nd Oct 20254:10 pmRNSDirector/PDMR Shareholding
30th Sep 202512:38 pmRNSHolding(s) in Company
23rd Sep 20257:05 amRNSDirectorate Changes
23rd Sep 20257:00 amRNSHalf Year Results
10th Sep 20252:14 pmRNSNotice of Results and Investor Presentation
31st Jul 20252:26 pmRNSDirectorate Change
8th Jul 202511:39 amRNSHolding(s) in Company
4th Jul 20255:55 pmRNSDirector/PDMR Shareholding
1st Jul 20258:00 amRNS-REquity Development Investor Presentation
1st Jul 20257:00 amRNSDefined Benefit Pension Scheme Update
1st Jul 20257:00 amRNSTrading Update
12th Jun 20255:40 pmRNSResult of AGM
6th Jun 20254:03 pmRNSHolding(s) in Company
23rd May 202511:38 amRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSNotice of AGM
8th May 20254:55 pmRNSDirector/PDMR Shareholding
2nd May 20251:03 pmRNSDirector/PDMR Dealing
29th Apr 20257:00 amRNSFinal Results
7th Apr 20257:00 amRNS-REquity Development Investor Presentation
24th Mar 202510:39 amRNSNotice of Results
25th Feb 20257:00 amRNS-RPension Scheme Valuation Update
23rd Jan 20258:32 amRNSHolding(s) in Company
16th Jan 20257:00 amRNSFull Year Trading update
7th Jan 20253:03 pmRNSHolding(s) in Company
29th Nov 20242:55 pmRNSCompletion of the Acquisition of CSi Palletising
5th Nov 202412:55 pmRNSStandard form for notification of major holdings
5th Nov 20249:39 amRNSStandard form for notification of major holdings
4th Nov 20248:57 amRNSStandard form for notification of major holdings
23rd Oct 20242:55 pmRNSStandard form for notification of major holdings
23rd Oct 202411:25 amRNSStandard form for notification of major holdings
18th Oct 20249:54 amRNSResult of General Meeting
8th Oct 20247:00 amRNSResult of Retail Offer
1st Oct 202412:05 pmRNSResult of Placing
1st Oct 20248:00 amRNSProposed Retail Offer to raise up to £1 million
1st Oct 20247:20 amRNSProposed Placing to raise £29 million
1st Oct 20247:00 amRNSAcquisition of CSi Palletising
24th Sep 202410:01 amRNSStandard form for notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.